Eli Lilly and Company (TSX:LLY)

Market Cap	1.37T
Revenue (ttm)	82.77B
Net Income (ttm)	25.65B
Shares Out	n/a
EPS (ttm)	28.47
PE Ratio	53.48
Forward PE	35.27
Dividend	n/a
Ex-Dividend Date	n/a

Volume	35,161
Average Volume	30,857
Open	38.90
Previous Close	38.60
Day's Range	38.90 - 40.52
52-Week Range	22.85 - 40.52
Beta	n/a
RSI	64.33
Earnings Date	Feb 6, 2026

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals in the United States, Europe, China, Japan, and internationally. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Ja...

• Industry: Pharmaceutical Preparations
• Founded: 1876
• Employees: 47,000
• Stock Exchange: Toronto Stock Exchange
• Ticker Symbol: LLY

Financial Performance

In 2024, Eli Lilly and Company's revenue was $45.04 billion, an increase of 32.00% compared to the previous year's $34.12 billion. Earnings were $10.59 billion, an increase of 102.08%.

Financial numbers in USD